Jazz Pharmaceuticals

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose and checks for side effects, and the second part measures how well the drug shr…

This study follows 70-100 people with Lennox-Gastaut, Dravet, or TSC who are already prescribed Epidyolex (a CBD liquid). Researchers will track how many stay on the drug for a year and how many seizure-free days they have. The goal is to see how well it works in everyday life, n…

This early-stage trial tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and understand side effects. About 102 participants will receive the drug weekly or multiple days per week.

This early-phase study tests a new experimental drug called JZP898, given alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and…

This study tests whether the drug ONC201 can help people with a rare and aggressive brain tumor called H3 K27M-mutant glioma live longer. Participants must have completed standard radiation therapy. The trial is double-blind, meaning neither patients nor doctors know who gets the…

This study tests whether adding zanidatamab to standard chemotherapy (with or without an immunotherapy drug) helps people with advanced HER2-positive biliary tract cancer live longer without their cancer growing. About 286 participants will be randomly assigned to receive either …

This early-phase study tests a new drug called JZP815 in adults with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 participants who have tried all other tr…

This study tests whether a new drug called zanidatamab, combined with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with advanced HER2-positive breast cancer that has worsened after or cannot tolerate a prior treatment. About 5…

This study tests a new drug called ONC206 in 90 people with advanced pheochromocytoma or paraganglioma, rare tumors that cannot be removed by surgery. The goal is to see if the drug can shrink tumors or stop them from growing. Participants must have tried or declined other treatm…

This study tests whether adding the drug zanidatamab to standard chemotherapy can completely eliminate cancer in the breast and armpit before surgery in people with early-stage HER2-positive breast cancer. About 125 adults with stage II or III disease will receive the combination…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study tests a cannabidiol (CBD) oral solution in 100 people aged 12 to 75 with focal-onset seizures. The goal is to see if CBD can reduce seizure frequency and is safe. Participants take the liquid medicine and track their seizures over time.

This early-stage study tests the safety and how the body processes a new drug called JZP047 in 86 healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and some take the drug with or without food to see if meals affect absorption. The goal is to gather …

This study follows 50 pregnant women who have taken the epilepsy medication Epidiolex (or Epidyolex) to see if it affects pregnancy outcomes or the health of their baby up to 12 months old. Researchers will track complications like birth defects, miscarriage, and preterm delivery…